Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Organon Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Organon kazanç ve gelirin sırasıyla yıllık 7.2% ve 0.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 6.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 97.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

7.2%

Kazanç büyüme oranı

6.8%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.8%
Gelir büyüme oranı	0.2%
Gelecekteki özkaynak getirisi	97.7%
Analist kapsamı	Good
Son güncelleme	18 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

Sep 19

Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year

May 29

Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals

May 10

Four Reasons Why Organon Stock Is A Good Buy

May 07

Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings

Apr 21

Organon Stock Is Still Worth A Look

Feb 24

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Feb 19

Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last

Feb 16

Organon: What I'm Looking For In This 8% Yield In 2024

Jan 03

High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued

Dec 19

Organon: It's Darkest Before The Dawn

Nov 30

Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace

Nov 07

Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28

Nov 05

Organon: The Federal Reserve Black Swan (Rating Upgrade)

Oct 04

6% Yield And Significantly Undervalued: A Closer Look At Organon

Sep 10

Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk

Aug 10

Organon & Co.: A Tough Spot To Be In Right Now

Jul 16

Organon goes ex-dividend tomorrow

Feb 23

Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 19

Is There Anything Organic Or Interesting About Organon?

Feb 07

Organon goes ex-dividend tomorrow

Nov 09

Organon's (NYSE:OGN) Dividend Will Be $0.28

Nov 08

Take Care Before Diving Into The Deep End On Organon & Co. (NYSE:OGN)

Nov 05

Organon: Thoughts Ahead Of Q3 Earnings

Oct 31

Organon: What Is The Recipe?

Aug 31

Oragenics announces early toxicology data for intranasal COVID-19 vaccine

Aug 24

Organon, Samsung Bioepis Humira biosimilar Hadlima high concentration dosage gets FDA nod

Aug 17

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Aug 07

Kazanç ve Gelir Büyüme Tahminleri

NYSE:OGN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	6,509	1,080	1,110	1,138	6
12/31/2025	6,470	979	1,055	1,109	7
12/31/2024	6,393	758	658	1,162	7
6/30/2024	6,346	1,000	787	1,066	N/A
3/31/2024	6,347	1,047	458	761	N/A
12/31/2023	6,263	1,023	538	799	N/A
9/30/2023	6,150	585	424	669	N/A
6/30/2023	6,168	754	320	725	N/A
3/31/2023	6,145	746	431	849	N/A
12/31/2022	6,174	917	431	858	N/A
9/30/2022	6,292	1,011	138	638	N/A
6/30/2022	6,355	1,107	343	689	N/A
3/31/2022	6,365	1,304	564	1,077	N/A
12/31/2021	6,304	1,351	1,970	2,458	N/A
9/30/2021	6,314	1,525	2,370	2,841	N/A
6/30/2021	6,327	1,762	2,304	2,761	N/A
3/31/2021	6,258	1,917	2,772	3,025	N/A
12/31/2020	6,532	2,256	1,932	2,187	N/A
12/31/2019	7,777	3,306	2,675	2,767	N/A
12/31/2018	9,777	2,153	3,586	3,687	N/A
12/31/2017	10,500	1,801	N/A	3,419	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: OGN 'nin tahmini kazanç büyümesi (yıllık 7.2% ) tasarruf oranının ( 2.5% ) üzerindedir.

Kazançlar ve Piyasa: OGN şirketinin kazançlarının (yıllık 7.2% ) US pazarından (yıllık 15.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: OGN şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: OGN şirketinin gelirinin (yıllık 0.2% ) US pazarından (yıllık 8.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: OGN şirketinin gelirinin (yıllık 0.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: OGN 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 97.7 %).

Organon Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Organon & Co. Affirms Revenue Guidance for the Full Year 2024

Organon & Co. Provides Earnings Guidance for the Year 2023

Consensus EPS estimates fall by 22%

Price target decreased by 13% to US$24.56

Organon & Co. Revises Earnings Guidance for the Full Year 2023

Price target decreased by 7.8% to US$28.38

Recent updates

Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

Organon & Co. (NYSE:OGN) agreed to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others for approximately $1.2 billion.

These 4 Measures Indicate That Organon (NYSE:OGN) Is Using Debt In A Risky Way

Organon & Co.: Cheap With Caveats

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Second quarter 2024 earnings released: EPS: US$0.76 (vs US$0.95 in 2Q 2023)

Insufficient Growth At Organon & Co. (NYSE:OGN) Hampers Share Price

Organon & Co. Affirms Revenue Guidance for the Full Year 2024

Investor sentiment deteriorates as stock falls 16%

Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum

Organon & Co. to Report Q2, 2024 Results on Aug 06, 2024

Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals

Four Reasons Why Organon Stock Is A Good Buy

First quarter dividend of US$0.28 announced

First quarter 2024 earnings released: EPS: US$0.79 (vs US$0.70 in 1Q 2023)

Organon & Co. Provides Earnings Guidance for the Year 2023

Organon & Co., Annual General Meeting, Jun 04, 2024

Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings

Organon & Co. to Report Q1, 2024 Results on May 02, 2024

CEO & Director exercised options and sold US$628k worth of stock

CEO & Director exercised options and sold US$729k worth of stock

Organon Stock Is Still Worth A Look

US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Fourth quarter dividend of US$0.28 announced

Full year 2023 earnings: EPS exceeds analyst expectations

Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last

Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024

Organon & Co. to Report Q4, 2023 Results on Feb 15, 2024

Investor sentiment improves as stock rises 18%

Organon’S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older

Organon: What I'm Looking For In This 8% Yield In 2024

High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued

Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024

Organon: It's Darkest Before The Dawn

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 22%

Samsung Bioepis & Organon Announces FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (Adalimumab-bwwd)

Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace

Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28

Price target decreased by 13% to US$24.56

Organon & Co. Declares a Quarterly Dividend, Payable on December 14, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Organon & Co. to Report Q3, 2023 Results on Nov 02, 2023

Organon: The Federal Reserve Black Swan (Rating Upgrade)

Organon & Co.(NYSE:OGN) dropped from FTSE All-World Index (USD)

Organon Announces First Real-World Observational Study of the JADA® System

6% Yield And Significantly Undervalued: A Closer Look At Organon

Organon Announces Two Leadership Appointments

Organon & Co. Revises Earnings Guidance for the Full Year 2023

Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Samsung Bioepis & Organon Announces Topline Results from Interchangeability Study of SB5 Humira Biosimilar

Price target decreased by 7.8% to US$28.38

Organon & Co. to Report Q2, 2023 Results on Aug 08, 2023

Organon & Co.: A Tough Spot To Be In Right Now

Organon & Co. & Samsungbioepis Co,.Ltd Announces US Launch of Humira Biosimilar Hadlima (adalimumab-Bwwd) in Multiple Presentations Consistent with Originator

Consensus EPS estimates fall by 16%

Organon & Co. Declares Guidance Quarterly Dividend, Payable on June 15, 2023

First quarter 2023 earnings: EPS misses analyst expectations

CEO & Director exercised options and sold US$275k worth of stock

CEO & Director exercised options and sold US$160k worth of stock

Organon goes ex-dividend tomorrow

Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2022 earnings: EPS misses analyst expectations

Organon Declares Quarterly Dividend, Payable on March 16, 2023